There’s No Getting Around Mangoceuticals Inc (NASDAQ: MGRX) Success

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted MANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITS.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

MGRX belongs to the Healthcare sector of the NASDAQ while operating in the Health Information Services industry. At the end of the last regular session, the stock closed at $0.40 and fluctuated between $0.4356 as its day high and $0.3505 as its day low. The current market capitalization of Mangoceuticals Inc is $8.79M. A total of 2.32 million shares were traded on the day, compared to an average of 723.62K shares.

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, MGRX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 3 BUYs and 0 SELLs from insiders. Insiders purchased 400,000 shares during that period but sold 0.

In the most recent transaction, Cohen Jacob D. bought 275,000 shares of MGRX for 1.00 per share on Apr 10. After the transaction, the Chief Executive Officer now owns 8,275,000 company shares.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, MGRX has a high of $4.37 and a low of $0.26.

As of this writing, MGRX has an earnings estimate of $MacroGenics, Inc. per share for the current quarter. EPS was calculated based on a consensus of Metagenomi, Inc. Common Stock estimates, with a high estimate of $Eagle Pharmaceuticals, Inc. per share and a lower estimate of $Agile Therapeutics, Inc.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. MGRX’s latest balance sheet shows that the firm has $22.55k in Cash & Short Term Investments as of fiscal 2021. There were $39.27k in debt and $39.27k in liabilities at the time. Its Book Value Per Share was $0.08, while its Total Shareholder’s Equity was -$16.72k.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock.

Most Popular

Related Posts